Veradermics, Inc (MANE) stock
MANENYSEPharmaceutical PreparationsFiscal year ends December 31
$125.64−2.41 (-1.88%)
Close on Nov 17, 2026Market cap $5.25BP/E –Yield –
Veradermics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$72.35M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$72.35M | – |
| FY2024 | Dec 31, 2024 | -$26.78M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$29.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$29.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.92M | – |
See a number that looks wrong?